Patents by Inventor Gloria C. Koo

Gloria C. Koo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6268155
    Abstract: A method for objectively quantitating the cellular infiltration in a tissue biopsy of a warm-blooded animal using a capture ELISA method. This method also allows one to quantitate the cellular infiltration of a tissue biopsy corresponding to an inflammatory response. As such this invention has both research and clinical applications in the analysis of an inflammatory response, and the effectiveness of immunosuppresants in addressing the inflammation.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: July 31, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Gloria C. Koo, Mai P. Nguyen, Althea D. Talento
  • Patent number: 5837220
    Abstract: A method for analyzing the immunosuppressant activity of Kv1.3 inhibitors using the mini- and micro-pig. These pig models have been found to have K.sub.v 1.3 channels very similar to man both in function and setting of membrane potential of T-lymphocytes, and respond similarly in a mixed lymphocyte reaction (MLR) to the K.sub.v 1.3 channel blockers. The mini-pig and micro-pig provide useful in vivo animal models for studying the immunosuppressant activity of Kv1.3 channel blockers that would be expected to function in man.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: November 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: J. Thomas Blake, William P. Feeney, Gloria C. Koo, Althea D. Talento
  • Patent number: 5494895
    Abstract: A thirty-nine amino acid peptide, Margatoxin (MgTX), is purified to homogeneity from venom of the scorpion Centruroides margaritatus. The gene encoding MgTX is constructed and this gene is expressed in E. coli, to produce recombinant MgTX. MgTX is a potent and selective inhibitor of a voltage-dependent K.sup.+ channel present in human lymphocytes. MgTX exhibits immunosuppressant activity with human T-lymphocytes, and is useful as an immunosuppressant, in modeling nonpeptidyl K.sup.+ channel blockers, and in establishing biochemical assays based on ligand binding or other protocols with which to screen for other novel modulators of voltage dependent K.sup.+ channels in lymphocytes and other tissues including the brain. As an immunosuppressant, MgTX is useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: February 27, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Gloria C. Koo, Reid J. Leonard, Chiu-Chuan S. Lin, Robert S. Slaughter, Scott P. Stevens, Joanne M. Williamson
  • Patent number: 4680258
    Abstract: Production of anti-H-Y hybridoma cell lines, and the use of the antibodies to determine the presence of H-Y antigen to indicate the sex of the proband inclusive of fetus, newborn and adult humans.
    Type: Grant
    Filed: August 9, 1983
    Date of Patent: July 14, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ulrich Hammerling, Gloria C. Koo, Nobuhiko Tada